NSE · GRANULES.NS
Granules India Limited
₹846.30+₹8.95 (+1.07%)
Granules India Limited’s quoted price sits in the upper half of its reported 52-week range, 8.49% below the high.
Loading market information…
NSE · GUFICBIO.NS · INR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 07:17 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Gufic Biosciences Limited’s quoted price sits in the upper half of its reported 52-week range, 10.43% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Gufic Biosciences Limited’s forward annual dividend is ₹0.10 per share, paid annual. The forward yield is 0.02% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Gufic Biosciences Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Gufic Biosciences Limited is an Indian enterprise dedicated to the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic medications, and related support services. The company's API and bulk drug offerings include antifungals, anesthetics, immunosuppressants, and intermediates for antifungal treatments. It also produces lyophilized injectable pharmaceuticals, covering diverse therapeutic areas such as antibiotics, antifungals, cardiac care, infertility solutions, antivirals, and proton-pump inhibitors. Additionally, Gufic Biosciences provides pharmaceutical products under its Spark, Criti Care, and Ferti Care brands, as well as a line of herbal and personal care items. The company distributes its extensive product portfolio to hospital networks and medical facilities, and it exports its goods to over twenty countries globally. Established in 1970, Gufic Biosciences Limited is headquartered in Mumbai, India.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:21 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹846.30+₹8.95 (+1.07%)
Granules India Limited’s quoted price sits in the upper half of its reported 52-week range, 8.49% below the high.
₹1,433.10+₹35.70 (+2.55%)
Alivus Life Sciences Limited’s quoted price sits in the upper half of its reported 52-week range, 4.36% below the high.
₹786.60-₹0.95 (-0.12%)
NATCO Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 35.88% below the high.
₹728.30-₹12.75 (-1.72%)
Akums Drugs & Pharmaceuticals Ltd.’s quoted price sits in the upper half of its reported 52-week range, 13.17% below the high.
₹113.35-₹5.96 (-5.0%)
Morepen Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 24.78% below the high.
₹2,653.10-₹350.70 (-11.68%)
RPG Life Sciences Limited’s quoted price sits in the upper half of its reported 52-week range, 15.18% below the high.
₹854.60-₹38.80 (-4.34%)
Orchid Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 25.26% below the high.
₹489.75-₹15.20 (-3.01%)
Unichem Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 28.73% below the high.
